Literature DB >> 34165324

Manual Reading of Sensititre Broth Microdilution System Panels Improves Accuracy of Susceptibility Reporting for Polymyxin Antibiotics.

Michelle M Bellerose1, Andrew E Clark1, Jung-Ho Youn1, Rebecca A Weingarten1, Chelsea M Crooks1, John P Dekker1,2, Karen M Frank1.   

Abstract

Accurate and reproducible antimicrobial susceptibility testing (AST) of polymyxin antibiotics is critical, as these drugs are last-line therapeutic options for the treatment of multidrug-resistant Gram-negative bacterial infections. However, polymyxin AST in the routine laboratory remains challenging. In this study, we evaluated the performance of an automated broth microdilution (BMD) system (Sensititre, ThermoFisher) compared to that of agar dilution (AD) for colistin and polymyxin B AST of 129 Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii complex clinical isolates. MICs derived from the Sensititre instrument based on two operator comparisons demonstrated overall categorical agreement (CA) of 86% and 89% compared to AD for colistin and 89% and 92% compared to AD for polymyxin B. However, error rates were higher than recommended by CLSI. Manual inspection of microdilution wells revealed microbial growth and skip wells which were erroneously interpreted by the Aris 2X instrument. Using manually interpreted BMD MICs read by two operators increased the overall categorical agreements to 88% and 95% compared to AD for colistin and 92% and 96% compared to AD for polymyxin B. Laboratories choosing to use the Sensititre platform for polymyxin AST should consider manual evaluation of wells as part of their algorithm.

Entities:  

Keywords:  Gram-negative bacteria; assay; clinical methods; colistin; diagnostic; polymyxin B; polymyxins; susceptibility

Mesh:

Substances:

Year:  2021        PMID: 34165324      PMCID: PMC8373007          DOI: 10.1128/JCM.00332-21

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  37 in total

Review 1.  Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.

Authors:  Laurent Poirel; Aurélie Jayol; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

2.  Colistin susceptibility test evaluation of multiple-resistance-level Pseudomonas aeruginosa isolates generated in a morbidostat device.

Authors:  Mumina Javed; Viola Ueltzhoeffer; Maximilian Heinrich; Hans Justus Siegrist; Ronja Wildermuth; Freia-Raphaella Lorenz; Richard A Neher; Matthias Willmann
Journal:  J Antimicrob Chemother       Date:  2018-12-01       Impact factor: 5.790

3.  Susceptibility Testing for the Polymyxins: Two Steps Back, Three Steps Forward?

Authors:  Shawn Vasoo
Journal:  J Clin Microbiol       Date:  2017-07-19       Impact factor: 5.948

4.  Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST).

Authors:  Jason M Pogue; Ronald N Jones; John S Bradley; David R Andes; Sujata M Bhavnani; George L Drusano; Michael N Dudley; Robert K Flamm; Keith A Rodvold; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

5.  Colistin and Polymyxin B Susceptibility Testing for Carbapenem-Resistant and mcr-Positive Enterobacteriaceae: Comparison of Sensititre, MicroScan, Vitek 2, and Etest with Broth Microdilution.

Authors:  Ka Lip Chew; My-Van La; Raymond T P Lin; Jeanette W P Teo
Journal:  J Clin Microbiol       Date:  2017-06-07       Impact factor: 5.948

6.  Polymyxin B Etest® compared with gold-standard broth microdilution in carbapenem-resistant Enterobacteriaceae exhibiting a wide range of polymyxin B MICs.

Authors:  B Kulengowski; J A Ribes; D S Burgess
Journal:  Clin Microbiol Infect       Date:  2018-04-16       Impact factor: 8.067

7.  Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.

Authors:  Mical Paul; George L Daikos; Emanuele Durante-Mangoni; Dafna Yahav; Yehuda Carmeli; Yael Dishon Benattar; Anna Skiada; Roberto Andini; Noa Eliakim-Raz; Amir Nutman; Oren Zusman; Anastasia Antoniadou; Pia Clara Pafundi; Amos Adler; Yaakov Dickstein; Ioannis Pavleas; Rosa Zampino; Vered Daitch; Roni Bitterman; Hiba Zayyad; Fidi Koppel; Inbar Levi; Tanya Babich; Lena E Friberg; Johan W Mouton; Ursula Theuretzbacher; Leonard Leibovici
Journal:  Lancet Infect Dis       Date:  2018-02-16       Impact factor: 25.071

Review 8.  A Review of the Clinical Pharmacokinetics of Polymyxin B.

Authors:  Sean N Avedissian; Jiajun Liu; Nathaniel J Rhodes; Andrew Lee; Gwendolyn M Pais; Alan R Hauser; Marc H Scheetz
Journal:  Antibiotics (Basel)       Date:  2019-03-22

Review 9.  Shifting Gears: The Future of Polymyxin Antibiotics.

Authors:  Justin R Lenhard; Zackery P Bulman; Brian T Tsuji; Keith S Kaye
Journal:  Antibiotics (Basel)       Date:  2019-04-12

10.  Colistin Heteroresistance Is Largely Undetected among Carbapenem-Resistant Enterobacterales in the United States.

Authors:  Victor I Band; Sarah W Satola; Richard D Smith; David A Hufnagel; Chris Bower; Andrew B Conley; Lavanya Rishishwar; Suzanne E Dale; Dwight J Hardy; Roberto L Vargas; Ghinwa Dumyati; Marion A Kainer; Erin C Phipps; Rebecca Pierce; Lucy E Wilson; Matthew Sorensen; Erik Nilsson; I King Jordan; Eileen M Burd; Monica M Farley; Jesse T Jacob; Robert K Ernst; David S Weiss
Journal:  mBio       Date:  2021-01-26       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.